Avenzo Therapeutics’ Post

𝙑𝙀𝙉𝙏𝙐𝙍𝙀 𝙄𝙉𝙑𝙀𝙎𝙏𝙈𝙀𝙉𝙏𝙎 𝙒𝙝𝙤 𝙬𝙖𝙣𝙩𝙨 𝙩𝙤 𝙗𝙚𝙘𝙤𝙢𝙚 𝙖𝙣 𝙪𝙣𝙞𝙘𝙤𝙧𝙣 𝘾𝙂 𝙊𝙣𝙘𝙤𝙡𝙤𝙜𝙮, is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. Urologic cancer patients can benefit from these innovative therapies to live and work with dignity and an enhanced quality of life. CG has 3 active clinical programs with planned studies soon underway. CG Oncology locked up a $105 million round co-led by new investors Foresite Capital and TCGX. California-based firm will use the new cash to advance latestage clinical programs for its bladder cancer treatment. Founded in 2010, the company has raised so far nearly $318 million. #investment #stockmarket #stockbroker #makemoney #exchange #ipo #join_ipo_deals_and_make_money #atranicapital

One of the critical issues when thinking about sponsorships is efficiency - how much it costs to engage with your stakeholders in order to ultimately improve patient treatment and outcomes. Our event scan shows that major players in oncology have wildly different levels of efficiency in their spend. Would you like to know how your company stacks up? #sponsorships #ASCO #oncology #efficiency

One of the critical issues when thinking about sponsorships is efficiency - how much it costs to engage with your stakeholders in order to ultimately improve patient treatment and outcomes. Our event scan shows that major players in oncology have wildly different levels of efficiency in their spend. Would you like to know how your company stacks up? #sponsorships #ASCO #oncology #efficiency

Discover how leveraging the detailed insights from the Keiretsu Due Diligence report empowers InnovoTEX Inc.  to navigate the complexities fundraising, as are securing pivotal funding for revolutionary ovarian cancer treatments. This video is a must-watch for investors looking to elevate their portfolio and founders seeking funding. #InvestmentInsights #DueDiligenceExcellence #KeiretsuForum"

#Asgard announces €30 million Series A financing! We are excited to announce today a Series A financing, co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.   Funds will be used to support development of our lead program, AT-108, a first-in-class, off-the-shelf intra-tumoral cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses. The financing will also be used for expanding Asgard's R&D team to further develop AT-108 and broaden our in vivo reprogramming #pipeline.   Click the link in the comments below to read the press release and discover more about Asgard's pioneering approach of in vivo direct cell reprogramming for #cancer #immunotherapy.   #lifesciences #biotech #oncology

#ASCO2024 it's just around the corner! Don't miss out on the opportunity to meet with our CEO, Rocio Arroyo, COO, Elena Sanchez Viñes, and CSO, Lourdes Planelles Carazo. You can reach out at their LinkedIn profiles to schedule a meeting!🧬🔬 We're excited to exchange ideas and insights with the oncology community. 💡 Learn about #Amadix and our latest advances in #EarlyCancerDetection. #ASCO2024 #Oncology #Innovation #cancerresearch

Discover how leveraging the detailed insights from the Keiretsu Due Diligence report empowers InnovoTEX Inc.  to navigate the complexities fundraising, as are securing pivotal funding for revolutionary ovarian cancer treatments. This video is a must-watch for investors looking to elevate their portfolio and founders seeking funding. #InvestmentInsights #DueDiligenceExcellence #KeiretsuForum"

Discover how leveraging the detailed insights from the Keiretsu Due Diligence report empowers InnovoTEX Inc.  to navigate the complexities fundraising, as are securing pivotal funding for revolutionary ovarian cancer treatments. This video is a must-watch for investors looking to elevate their portfolio and founders seeking funding. #InvestmentInsights #DueDiligenceExcellence #KeiretsuForum"

Did you miss the 2024 ASCO Annual Meeting? Our analysts at Biomedtracker have you covered! Download our comprehensive post-event report recapping key presentations, announcements, and advances shared. https://ow.ly/Hzzh50Sr0Xa Stay up-to-date with the latest trends and breakthroughs in oncology research. Download the report today and share with your colleagues. #ASCO2024 #Oncology #Biomedtracker #ASCOHighlights #OncologyInsights #BiomedAnalysis

The HiRO GO model is more than a strategy; it’s a paradigm shift. By harmonizing the strengths of the APAC region, HiRO offers a cohesive, streamlined approach to oncology trials that encompasses expert local knowledge and global reach. Learn more in our detailed blog. https://lnkd.in/gdmT8jrq #ClinicalTrials #Oncology #HiRO